Nitroreductase-based GDEPT
- PMID: 12052212
- DOI: 10.2174/1381612023394584
Nitroreductase-based GDEPT
Abstract
Nitroreductases that metabolise aromatic nitro groups to hydroxylamines are attractive as enzymes for GDEPT because of the very large electronic change that this metabolism generates, providing an efficient switch that can be exploited to generate potent cytotoxins. While nitroreductase enzymes are widespread, nearly all the work using these in GDEPT has been with the nfsB gene product of Escherichia coli, an oxygen-insensitive flavin mononucleotide nitroreductase (NTR). Four classes of prodrugs for NTR have been described; dinitroaziridinylbenzamides, dinitrobenzamide mustards, 4-nitrobenzylcarbamates and nitroindolines. While some quinones are excellent substrates for NTR, none have been identified as potential GDEPT prodrugs. The most widely studied prodrug used for GDEPT in conjunction with NTR is the dinitroaziridinylbenzamide CB 1954. This shows high selectivity (>1000-fold) in cell lines transfected with NTR, has potent and long-lasting inhibition of NTR-transfected tumours in mice, and is in Phase I trial in conjunction with virally-delivered NTR enzyme. The related mustard SN 23862 has similar selectivity and superior bystander effects in animal models. Nitrobenzyl carbamates of a variety of cytotoxic amines (including aniline mustards, enediynes, duocarmycin analogues, pyrrolobenzodiazepines and the antitumour antibiotics doxorubicin, actinomycin D and mitomcyin C) are metabolised efficiently by NTR to the hydroxylamines, that fragment to release the amines. Nitroindoline derivatives of duocarmycins also show moderate selectivity for NTR-transfected cell lines in culture.
Similar articles
-
2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.Br J Cancer. 2004 Mar 8;90(5):1084-92. doi: 10.1038/sj.bjc.6601612. Br J Cancer. 2004. PMID: 14997211 Free PMC article.
-
Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.J Med Chem. 2007 Mar 22;50(6):1197-212. doi: 10.1021/jm061062o. Epub 2007 Feb 28. J Med Chem. 2007. PMID: 17326614
-
Aziridinyldinitrobenzamides: synthesis and structure-activity relationships for activation by E. coli nitroreductase.J Med Chem. 2004 Jun 3;47(12):3295-307. doi: 10.1021/jm0498699. J Med Chem. 2004. PMID: 15163209
-
CB 1954: from the Walker tumor to NQO2 and VDEPT.Curr Pharm Des. 2003;9(26):2091-104. doi: 10.2174/1381612033454108. Curr Pharm Des. 2003. PMID: 14529407 Review.
-
Mechanism of CB1954 reduction by Escherichia coli nitroreductase.Biochem Soc Trans. 2009 Apr;37(Pt 2):413-8. doi: 10.1042/BST0370413. Biochem Soc Trans. 2009. PMID: 19290872 Review.
Cited by
-
Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs.ChemMedChem. 2016 Nov 7;11(21):2410-2421. doi: 10.1002/cmdc.201600417. Epub 2016 Oct 5. ChemMedChem. 2016. PMID: 27706901 Free PMC article.
-
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.Stem Cells. 2010 Jun;28(6):1107-15. doi: 10.1002/stem.433. Stem Cells. 2010. PMID: 20506146 Free PMC article.
-
Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.BMC Cancer. 2013 Mar 13;13:113. doi: 10.1186/1471-2407-13-113. BMC Cancer. 2013. PMID: 23497118 Free PMC article.
-
Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.Pharmaceuticals (Basel). 2022 Feb 1;15(2):185. doi: 10.3390/ph15020185. Pharmaceuticals (Basel). 2022. PMID: 35215297 Free PMC article.
-
Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System.Front Pharmacol. 2021 Jun 7;12:701456. doi: 10.3389/fphar.2021.701456. eCollection 2021. Front Pharmacol. 2021. PMID: 34163368 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases